applied genomics

applied genomics

Molecular genetics Molecular medicine The use of genetic information to diagnose, prognosticate and manage disease, based on the techniques of PCR, real time-PCR, DNA sequencing, and gene rearrangement studies for leukemia and lymphoma. See Gene rearrangement, Genetics, In situ hybridization, PCR.
Mentioned in ?
References in periodicals archive ?
Aevi Genomic Medicine and Kyowa Hakko Kirin have developed a collaboration framework to advance preclinical programs into the clinic, leveraging Aevi Genomic Medicine's expertise in rare and orphan pediatric diseases, and its ongoing collaboration with Children's Hospital of Philadelphia (CHOP) and the biobank at the Center for Applied Genomics at CHOP.
US applied genomics company Exact Sciences (NASDAQ:EXAS) is developingA Cologuard usingA MdxHealth'sA methylation biomarker and methylation-specific PCR technology.
The conference - regarded as one the top scientific gathering for genome sciences - is designed to share ground-breaking research in basic and applied genomics and to advance new approaches to sequencing and bioinformatics.
associate director of the Center for Applied Genomics at The Children's Hospital of Philadelphia.
Michael Mengel, PhD, a pathologist and lead researcher with the Alberta Transplant Applied Genomics Center, has developed gene-chip technology to assess damage that has occurred to transplanted kidneys and hearts.
Hakon Hakonarson, who is leading the new Center for Applied Genomics.
A multi-disciplined team from DSM applied genomics technology to degrade the free amino acid L-asparagine, the precursor to acrylamide, which was first detected at alarmingly high levels in foods by Swedish researchers in April 2002.
This increase was due to instrument sales growth in each of Applied Biosystems' three major product categories (DNA Sequencing, SDS and Other Applied Genomics, and Mass Spectrometry), which more than offset the decrease in instrument sales primarily in the Other Product Lines product category.
454 Life Sciences, an innovative developer of genome-scale sequencing technologies and a majority-owned subsidiary of CuraGen Corporation (NASDAQ: CRGN), has obtained an exclusive license for sole use of sequencing by synthesis and pyrophosphate based sequencing for whole genome applications from Pyrosequencing AB (Stockholm: PYRO A), a global technology solutions provider for the Applied Genomics market.
The money, from the government's DTI Link Applied Genomics Programme, has been awarded to Professor John Davey, of the department of biological sciences at the university, in partnership with Oxford-based biotech company, Oxagen and Coventry-based biotech company, Septegen.
com) announces updates to their Applied Genomics research database.
Previously, Barry served as the vice president of applied genomics at Illumina (NASDAQ: ILMN) where she integrated market development strategies with product and business model innovation to accelerate the application of genomics in medicine and personal healthcare.

Full browser ?